Mycophenolate mofetil therapy for children with intractable nephrotic syndrome

Background: Cyclosporin A (CyA) can suppress relapses and reduce proteinuria in frequent‐relapse nephrotic syndrome (FRNS) and steroid‐resistant nephrotic syndrome (SRNS). However, some patients remain resistant to CyA therapy. The purpose of the present paper was to evaluate mycophenolate mofetil (MMF) treatment in pediatric patients with CyA‐resistant intractable nephrotic syndrome.

[1]  L. Shaw,et al.  The Rationale for and Limitations of Therapeutic Drug Monitoring for Mycophenolate Mofetil in Transplantation , 2005, Transplantation.

[2]  D. Roth,et al.  Sequential therapies for proliferative lupus nephritis. , 2004, The New England journal of medicine.

[3]  N. Cengiz,et al.  Mycophenolate mofetil in children with multidrug-resistant nephrotic syndrome. , 2004, Clinical nephrology.

[4]  Arvind Bagga,et al.  Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  J. Flynn,et al.  Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome , 2003, Pediatric Nephrology.

[6]  U. Querfeld,et al.  Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil , 2003, Pediatric Nephrology.

[7]  D. Adu,et al.  Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  N. Yoshikawa,et al.  Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. , 2002, Kidney international.

[9]  J. Eustace,et al.  Mycophenolate mofetil treatment for primary glomerular diseases. , 2002, Kidney international.

[10]  G. Appel,et al.  Use of mycophenolate mofetil in resistant membranous nephropathy. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  M. Susin,et al.  Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil , 2000, Pediatric Nephrology.

[12]  M. Kimura,et al.  Low protein diet exacerbates NO synthase inhibitor-induced hypertension in rats , 1999, Clinical and Experimental Nephrology.

[13]  K. Yoshioka,et al.  Cyclosporine Therapy in Children with Steroid-resistant Nephrotic Syndrome , 1999 .

[14]  D. Cattran,et al.  Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  K. Yoshioka,et al.  Follow-up study of children with nephrotic syndrome treated with a long-term moderate dose of cyclosporine. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  E. Kohaut,et al.  Therapy of focal and segmental glomerulosclerosis with methylprednisolone, cyclosporine A, and prednisone , 1998, Pediatric Nephrology.

[17]  P. Halloran,et al.  Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. , 1997, Transplantation.

[18]  E. Ingulli,et al.  Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis. , 1995, Journal of the American Society of Nephrology : JASN.

[19]  A. Allison,et al.  Immunosuppressive and other Effects of Mycophenolic Acid and an Ester Prodrug, Mycophenolate Mofetil , 1993, Immunological reviews.